

Supplemental.




Fig. 1 Supplemental: Survival curves for mean tumour absorbed dose and disease progression, per-patient analysis. **a.** Difference in PFS between patients receiving an overall average tumour absorbed dose above or below 80 Gy. **b.** Difference in PFS between patients receiving an overall average tumour absorbed dose above or below 120 Gy.




Fig. 2 Supplemental: Survival curves for mean tumour dose and overall survival, per-patient analysis. **a.** Difference in OS between patients receiving an overall average tumour absorbed dose above or below 80 Gy. **b.** Difference in OS between patients receiving an overall average tumour absorbed dose above or below 120 Gy.

Clinical Toxicity

	B	S.E.	Wald	df	Sig.	Exp(B)
CTCAE	1,673	,693	5,820	1	,016	5,328

Labarotory Toxicity

	B	S.E.	Wald	df	Sig.	Exp(B)
CTCAE	,259	,385	,453	1	,501	1,296

Table 1 Supplemental: Logistic regression model with dichotomizing healthy liver mean dose (Dh) in in <30 and > 30 Gy for clinical and laboratory toxicity.